Nav: Home

Science News | Science Current Events | Brightsurf | October 09, 2016


Nivolumab reduces symptoms in relapsed metastatic head and neck cancer
Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congress in Copenhagen1 and published in the New England Journal of Medicine.
Pembrolizumab new option in 1-line treatment of adv lung cancer and high PD-L1 expression
Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
Are natural alternatives to estrogen replacement therapy safe?
Although individuals often consume natural products because of their potential health benefits, a new review indicates that it is not clear whether the benefits of plant-derived compounds that mimic estrogen outweigh the possible health risks.
Nivolumab reduces symptoms in relapsed metastatic head and neck cancer
Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congress in Copenhagen1 and published in the New England Journal of Medicine.
'Game-changing' immunotherapy doubles head and neck cancer survival
An immunotherapy drug has been hailed as a potential 'game changer' after being found to greatly improve survival for patients with relapsed head and neck cancer -- a disease which is notoriously difficult to treat.
Significant survival gains with atezolizumab vs. docetaxel for non-small-cell lung cancer
The first phase III study of PD-L1 inhibitor atezolizumab in previously treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers reported today at the ESMO 2016 Congress in Copenhagen.
Greater patient selection may be needed for 1st line nivolumab to improve progression-free survival
Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a broad group of patients expressing PD-L1 in their tumor cells.
First-line pembrolizumab plus chemotherapy improves outcomes in advanced NSCLC
The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers reported at the ESMO 2016 Congress in Copenhagen today.
Cell protein offers new hope in fighting the effects of aging
A protein found within the powerhouse of a cell could be the key to holding back the march of time, research by scientists at The University of Nottingham has shown.
New spin on nanofibers
Researchers have developed a new method to make nanofibers that could lead to stronger, more durable bulletproof vests and armor and more robust cellular scaffolding for tissue repair.
Ceritinib provides longer PFS than chemo in phIII trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen.
Nintedanib improves progression-free survival in metastatic colorectal cancer
Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial presented at the ESMO 2016 Congress in Copenhagen.
Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer
The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers reported today at the ESMO 2016 Congress in Copenhagen.
Ceritinib improves progression-free survival in phase 3 trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen.

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab